Children with cancer tumors lacking DNA repair may benefit from olaparib combined with ceralasertib.

Published Date: 19 Apr 2023

Pediatric patients with solid tumors exhibiting DNA replication stress and/or DNA repair responded favorably to a combination of the investigational ATR inhibitor ceralasertib and the PARP inhibitor olaparib (Lynparza).

Read Full News

Latest News

Single-dose radiation before surgery can eradicate breast cancer

A single, targeted high dose of radiation delivered before other treatments could completely eradicate tumors in most women with early-stage, operable hormone-positive breast cancer, according to a study led by UT Southwestern ...

Why palliative care goes hand in hand with treatment for people with cancer: Q&A

For many people with cancer and other serious diseases, palliative care is an important element of their journey.

Q&A: Odds of surviving cancer drop drastically when credit score dips

While past studies have explored how cancer patients' financial health influenced their risk of mortality, new research digs in deeper by zeroing in on objective data: credit scores.

Traces of bacteria inside brain tumors may affect tumor behavior

Researchers at The University of Texas MD Anderson Cancer Center have uncovered unexpected traces of bacteria within brain tumors. This discovery offers new insights into the environment in which brain tumors grow and sets ...

Cancer care crowdfunding increasingly common, but rarely successful

A growing number of desperate cancer survivors are turning to crowdfunding to help pay for their treatment and living expenses, a new study says.

Food insecurity linked to tumor growth in pediatric neuroblastoma

Neuroblastoma remains one of the deadliest childhood malignancies, accounting for a disproportionate number of pediatric cancer deaths worldwide.

Todays Updates

Rheumatology in 2025: Year in Review Victoria Johnson

The rheumatology year in review highlights FDA approvals and pivotal data readouts.

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point Victoria Johnson

Johnson & Johnson plans to initiate a phase 3 study based off the positive data.

Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1 Louie Pasculli

Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.

Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow Marco Meglio

Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis Marco Meglio

The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Todays Updates

Rheumatology in 2025: Year in Review Victoria Johnson

The rheumatology year in review highlights FDA approvals and pivotal data readouts.

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point Victoria Johnson

Johnson & Johnson plans to initiate a phase 3 study based off the positive data.

Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1 Louie Pasculli

Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.

Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow Marco Meglio

Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis Marco Meglio

The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Latest News

A single, targeted high dose of radiation delivered before other treatments could completely eradicate tumors in most women with early-stage, operable hormone-positive breast cancer, according to a study led by UT Southwestern ...

For many people with cancer and other serious diseases, palliative care is an important element of their journey.

While past studies have explored how cancer patients' financial health influenced their risk of mortality, new research digs in deeper by zeroing in on objective data: credit scores.

Researchers at The University of Texas MD Anderson Cancer Center have uncovered unexpected traces of bacteria within brain tumors. This discovery offers new insights into the environment in which brain tumors grow and sets ...

A growing number of desperate cancer survivors are turning to crowdfunding to help pay for their treatment and living expenses, a new study says.

Neuroblastoma remains one of the deadliest childhood malignancies, accounting for a disproportionate number of pediatric cancer deaths worldwide.

News All Time

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace

Bacteria are rapidly emerging as a new class of "living medicines" used to kill cancer cells.

Study shows supervised exercise improves strength, physical performance in patients with advanced breast cancer

Aerobic and resistance exercise can significantly improve physical performance in patients living with metastatic breast cancer, according to new results presented at the Advanced Breast Cancer Eighth International Consensus ...

Combination treatment may help cut lifelong ibrutinib for chronic lymphocytic leukemia patients

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western Hemisphere, affecting approximately 200,000 people in the United States.

Advanced breast cancer patients living longer thanks to improvements in treatment and care

People diagnosed with advanced breast cancer in 2025 can expect to live for an extra six or seven months, compared to the average survival time for patients diagnosed in 2011, according to a major study of patient data in ...

Radiotherapy after mastectomy can be avoided, study finds

Radiotherapy can be safely omitted as a treatment for many breast cancer patients who have had a mastectomy and are taking anti-cancer drugs, a study shows.

Data-driven risk stratification guides childhood brain tumor treatment, reducing side effects

By analyzing data from three clinical trials treating children with the brain tumor medulloblastoma, scientists at St. Jude Children's Research Hospital have designed an approach to safely reduce therapy, thereby lowering ...

Sustained reduction found in prostate cancer mortality with prostate-specific antigen screening

A European study has demonstrated a sustained long-term reduction in prostate cancer mortality through prostate-specific antigen (PSA) screening. However, the findings also highlight the issue of overdiagnosis, or the detection ...

How access to specialized cancer centers affects glioblastoma outcomes

Glioblastoma is one of the most aggressive and complex brain cancers. It grows quickly, resists standard treatments, and often leaves patients and their families searching for every possible option.

Is global cancer care losing its human touch?

A new Lancet Oncology Commission highlights a growing "human crisis" in cancer care. Despite advances in treatment and increased survival rates, many patients worldwide are not receiving the compassionate, holistic support ...

Indoor hydroponic gardening can improve mental health and quality of life for cancer patients

Indoor hydroponic gardening—a method of growing plants using nutrient-rich water instead of soil—could help cancer patients develop better mental health, eat a healthier diet and enjoy a better overall quality of life.

Clinical trial sees dramatic results using radiation to treat breast cancer

Almost immediately after Theresa Greco was diagnosed with breast cancer in March, doctors asked her whether she wanted to participate in a clinical trial. The trial would do high-powered radiation targeted at her tumor prior ...

Dual-action mRNA vaccine takes aim at aggressive skin cancer

Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting the protein essential to tumor cell growth and by adding a key signal to boost the immune system response. ...

For incarcerated people, study shows gaps exist in quality of cancer care

In the United States, the incarcerated population is aging. About 15% of incarcerated adults, or approximately 175,000 people, are now 55 years or older.

Molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target

Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and most comprehensive molecular analysis of renal medullary carcinoma (RMC), a rare and aggressive ...

FDA approves Blenrep for relapsed or refractory multiple myeloma

The U.S. Food and Drug Administration approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.

Radiation therapy for patients with breast cancer

Radiation therapy is a common component of breast cancer treatment for patients. The high-powered beams of intense energy kill cancer cells and reduce the risk of the cancer recurring.

Recommended News For You

NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.

What Could This Exploratory 5-Year Survival Data in Adjuvant NSCLC Treatment Mean?

Short Shrift in Cancer Funding; Bypassing Familiar for Distant; Testing for BRCA.

Legal, Recreational Marijuana Linked to Higher CUD Prevalence.

Children with cancer tumors lacking DNA repair may benefit from olaparib combined with ceralasertib.

Radiotherapy after mastectomy can be avoided, study finds

Preoperative Embolization Linked to Relapse-Free Survival in Meningioma

Recommended Articles For You

PARP Inhibitors in Testicular Cancer: Tackling Cisplatin Resistance with Precision 

The Importance of Having a Quick and Effective Heparin Antidote  

Unlocking the Potential of Red Bone Marrow in the Formation of Blood Cells 

The Lung Cancer Shift: From Reactive Treatment to Proactive Precision Medicine 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

As EGFR internalization is decreased, BUB1 controls EGFR signaling.

2.

A paper strip test might enable the early detection of cancer.

3.

Breast cancer patients' arms swell less after an effective lymph node transfer.

4.

A First in Total Larynx Transplant; 'Sniffing' Out Lung Cancer; Gen X Cancer Toll

5.

For fit patients with CLL, frontline venetoclax-ibrutinib improves survival.

1.

CENP-H in Cancer: A Key Player in Tumor Progression and a Potential Therapeutic Target

2.

Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment

3.

Seeing the Unseen: Examining Chancroid Through Images

4.

Beyond the Standard: Personalized Cancer Vaccines and the Dawn of a New Era in Pediatric Oncology

5.

Unveiling the Mystery of Epstein-Barr Virus: What We Know So Far

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Efficient Management of First line ALK-rearranged NSCLC

2.

Navigating the Complexities of Ph Negative ALL - Part IV

3.

Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.

4.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

5.

Efficient Management of First line ALK-rearranged NSCLC - Part VI

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot